Recombinant virus immunotherapy
OwnerEnzo Paoletti, James Tartaglia +1inventors
InventorsEnzo Paoletti, James Tartaglia, William I. Cox
Life of this patent
Estimating the term…
Abstract
Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFNg; IL-4; GNCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.
Claims16
A method for eliciting an anti-tumor response in a patient having a tumor, wherein the method comprises administering to the patient a recombinant vaccinia virus wherein regions C7L−K1L, J2ER, B13R+B14R, A56R, A26R and I4L have been deleted therefrom;
- or wherein the open reading frames for the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the hemagluttinin gene, the host range gene region, and the gene for the large subunit of ribonucleotide reductase have been deleted therefrom;
- and wherein the virus further comprises at least one exogenous DNA sequence encoding at least a portion of a tumor antigen expressed by the tumor.
Dependencies are inferred from the claim text.